MELOXICAM; RIZATRIPTAN BENZOATE - Generic Drug Details

What are the generic drug sources for meloxicam; rizatriptan benzoate and what is the scope of freedom to operate?

Meloxicam; rizatriptan benzoate is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are seventy-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Meloxicam; rizatriptan benzoate has two hundred and twelve patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for MELOXICAM; RIZATRIPTAN BENZOATE

International Patents:	212
US Patents:	75
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MELOXICAM; RIZATRIPTAN BENZOATE
DailyMed Link:	MELOXICAM; RIZATRIPTAN BENZOATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MELOXICAM; RIZATRIPTAN BENZOATE

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MELOXICAM; RIZATRIPTAN BENZOATE

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for MELOXICAM; RIZATRIPTAN BENZOATE

M01AC	Oxicams
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for MELOXICAM; RIZATRIPTAN BENZOATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBRAVO	Tablets	meloxicam; rizatriptan benzoate	20 mg/10 mg	215431	1	2025-06-30

US Patents and Regulatory Information for MELOXICAM; RIZATRIPTAN BENZOATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	11,045,549
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,471,069
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,195,278
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,265,324

International Patents for MELOXICAM; RIZATRIPTAN BENZOATE

Country	Patent Number	Title	Estimated Expiration
Chile	2021002070
Australia	2023202545
Brazil	112020026965
Hungary	E058677

Market Dynamics and Financial Trajectory for Meloxicam and Rizatriptan Benzoate

Last updated: August 1, 2025

Introduction

The pharmaceutical landscape is continually evolving, driven by novel therapeutic innovations, regulatory shifts, and changing patient demographics. Two notable drugs, Meloxicam and Rizatriptan Benzoate, exemplify medications with distinct clinical indications—osteoarthritis and rheumatoid arthritis for Meloxicam, and migraine relief for Rizatriptan Benzoate. Their market dynamics and financial trajectories reflect broader trends within the analgesic and anti-migraine segments, underscoring opportunities and challenges faced by industry stakeholders.

---

Drug Profiles and Therapeutic Roles

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the oxicam class. It primarily manages inflammatory conditions like osteoarthritis and rheumatoid arthritis by inhibiting cyclooxygenase (COX-2). Its advantages include a more selective COX-2 inhibition profile, resulting in reduced gastrointestinal side effects compared to traditional NSAIDs [1].

Rizatriptan Benzoate is a selective 5-HT_1B/1D receptor agonist classified as a triptan. It effectively aborts migraine episodes, providing rapid relief. Rizatriptan's fast onset and tolerability profile have made it a preferred choice for acute migraine management [2].

---

Market Dynamics

Market Size and Growth Drivers

Meloxicam

The global NSAID market is projected to reach USD 13.95 billion by 2028, with a compounded annual growth rate (CAGR) of approximately 4.2% from 2021 to 2028 [3]. Meloxicam benefits from increasing aging populations and rising prevalence of arthritis, fueling demand in developed and developing markets. The chronic nature of osteoarthritis sustains steady prescription rates, especially in Europe and North America.

Rizatriptan Benzoate

The global migraine treatment market is estimated to reach USD 14.6 billion by 2027, expanding at a CAGR of around 4.5% from 2020 to 2027 [4]. Rizatriptan, as a fast-acting triptan, maintains a significant share within the acute migraine segment. The rising burden of migraine and increased awareness of targeted therapies drive market expansion.

Competitive Landscape

Meloxicam

Market competition involves both originator brands and numerous generics. Major players include Boehringer Ingelheim, Sandoz (Novartis), and Mylan. The expiration of patent protections for Meloxicam in several regions—particularly in the US in 2016—has led to increased generic penetration, exerting downward pressure on prices.

Rizatriptan Benzoate

Originally developed by Merck (brand name Maxalt), Rizatriptan faces competition from other triptans like sumatriptan, eletriptan, and naratriptan. Patent expirations have introduced generics, significantly impacting pricing and market share dynamics. Despite intense competition, Rizatriptan remains competitive due to its favorable pharmacokinetics.

Regulatory and Patent Trends

Patents protect the exclusivity of many branded formulations; however, patent cliffs for both drugs have facilitated generic market entry. The regulatory landscape also influences market dynamics; post-approval label expansions and off-label use can impact potential revenue streams.

Pricing Trends and Reimbursement

Generic proliferation has led to substantial price erosion, particularly for Meloxicam, where prices have declined by over 50% since patent expiry. Reimbursement policies, especially in the US, influence access and sales volume. For Rizatriptan, private insurance coverage significantly affects patient uptake, with discounted generics further reducing costs.

---

Financial Trajectory and Market Opportunities

Revenue Trends

The revenue trajectories for pharmaceutical companies marketing Meloxicam and Rizatriptan are increasingly shaped by generic competition. Innovative formulations—such as transdermal patches for Meloxicam or orally disintegrating tablets for Rizatriptan—offer potential revenue growth avenues.

Emerging Market Penetration

Developing countries demonstrate increasing adoption due to rising healthcare infrastructure and prevalence of chronic pain and migraine. Companies focusing on localized manufacturing and tailored pricing strategies can capitalize on these markets.

Research and Development (R&D)

R&D initiatives aim at enhancing drug efficacy, safety profiles, and delivery methods. For Meloxicam, novel formulations with improved gastrointestinal safety will sustain demand. For Rizatriptan, formulations with reduced cardiovascular risks and longer duration of action are under investigation.

Digital and Personalized Medicine

Digital health integrations, such as mobile apps for migraine tracking and adherence, provide ancillary revenue streams. Personalized medicine approaches, including pharmacogenomics, could optimize therapy choices and patient outcomes, influencing future sales.

Risks and Challenges

Market saturation, price competition from generics, and regulatory hurdles pose significant risks. Additionally, safety concerns—particularly gastrointestinal and cardiovascular adverse effects—may impact prescribing trends.

---

Conclusion

The market for Meloxicam and Rizatriptan Benzoate is characterized by maturation, intense generic competition, and evolving therapeutic innovation. Strategic focus on differentiated formulations, emerging markets, and digital health integration will shape their financial trajectories. Companies that adapt swiftly to patent expirations, regulatory changes, and shifting consumer preferences will optimize revenue potential in these segments.

---

Key Takeaways

• Market maturity and patent expirations have resulted in increased generic competition, exerting downward pressure on drug prices for both Meloxicam and Rizatriptan.
• Demand drivers include aging populations with chronic inflammatory conditions and rising migraine prevalence, especially in emerging markets.
• Innovative formulations and delivery methods could offer differentiation and new revenue streams.
• Pricing and reimbursement strategies are critical in stabilizing revenues amid intense price competition.
• Digital health tools and personalized medicine represent promising avenues to enhance market share and patient engagement.

---

FAQs

1. How have patent expirations impacted the revenue of Meloxicam?
Patent expirations, notably in 2016 in the US, have led to a surge in generic versions, significantly reducing branded drug revenues and intensifying price competition.

2. What are the main drivers for Rizatriptan's market growth?
The increasing global burden of migraines and the drug’s favorable efficacy and tolerability profile drive its ongoing demand, complemented by brand and generic competition.

3. Are there new formulations of Meloxicam or Rizatriptan that could impact their markets?
Yes. For Meloxicam, transdermal patches and long-acting formulations are under development. Rizatriptan’s newer formulations aim to improve onset time and tolerability, potentially expanding patient options.

4. What challenges do companies face in sustaining profits for these drugs?
Key challenges include generic price erosion, regulatory hurdles, safety concerns, and market saturation.

5. How can manufacturers leverage emerging markets for growth?
Targeted pricing, local manufacturing, education campaigns, and tailored formulations can enhance penetration and revenue in emerging regions.

---

References:

[1] US Food and Drug Administration. Meloxicam (Mobic) Drug Label. Retrieved from FDA database.
[2] Merck & Co. Rizatriptan (Maxalt) Prescribing Information.
[3] Grand View Research. NSAID Market Size, Share & Trends Analysis. 2021-2028.
[4] Fortune Business Insights. Migraine Drugs Market Insights, 2020-2027.